Experimental cell therapy targets tough lupus cases
NCT ID NCT07339332
Summary
This early-stage study is testing a new type of cell therapy called universal CD19/CD20 CAR-T for people with moderate to severe lupus that hasn't improved with standard treatments. The main goals are to find a safe dose and see how the body reacts to the treatment. Researchers will enroll about 12 adults to receive an infusion of these specially engineered immune cells and monitor them closely for side effects and any signs of improvement in their lupus symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospita
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.